XERS News and Press, Xeris Pharmaceuticals Inc. From 05/09/20

Image source: The Motley Fool. Xeris Pharmaceuticals, Inc.   (NASDAQ: XERS) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading

Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Allison Wey – Senior Vice President-Investor Relations and Corporate Communication Paul Edick – Chairman and Chief Executive Officer Barry Deutsch –...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$0.89 misses by $0.05 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in July 2020 Initiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic Corporate actions taken to conserve ca...

Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, recently announced that it will release its first quarter 2020 financial results ...

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarte...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it has extended its $0 copay offer for Gvoke™ Pre-F...

Nano cap Xeris Pharmaceuticals (NASDAQ: XERS ) is up  19%  premarket on light volume in reaction to results from a Phase 1b study assessing two dose levels of its injectable formulation of diazepam in 20 healthy volunteers. More news on: Xeris Pharmaceuticals, Inc., Healthcare ...

Xeris’ IM diazepam maintains higher concentration over longer time period versus standard of care Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and in...

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon re...